Drug intelligence / Profile preview

NPC01

Development stage
Preclinical
Lead developer
Tianjin Medical University Cancer Institute and Hospital
Administration
Oral
01

Overview

NPC01 is an oral multi-herb traditional Chinese medicine formula, modified from Liang-Ge-San, developed and used at Tianjin Medical University Cancer Institute & Hospital for nasopharyngeal carcinoma and other head and neck cancers. In preclinical nasopharyngeal carcinoma models, NPC01 inhibited proliferation, induced apoptosis, and demonstrated antiangiogenic activity associated with suppression of the PI3K/Akt/mTOR signaling pathway and reduced HIF-1α and VEGF expression. A retrospective clinical study reported improvements in cancer-related symptoms and health-related quality-of-life measures among patients with head and neck cancer receiving the formula. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC5831941/))

Other names
Traditional Chinese medicine formula 01 for nasopharyngeal carcinoma
02

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)VEGFA (Vascular endothelial growth factor A)HIF1A (Hypoxia-inducible factor 1-alpha)

Beyond the preview

Go deeper on NPC01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NPC01.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call